DJIA 17,043.51 60.92 0.36%
NASDAQ 4,466.13 21.22 0.48%
S&P 500 1,983.40 4.49 0.23%
market minute promo


133.52 -0.39 (-0.29%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

BAYRY $133.52 -0.29%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $133.31
Previous Close $133.90
Daily Range $133.22 - $134.10
52-Week Range $108.45 - $145.20
Market Cap $110.4B
P/E Ratio 743.89
Dividend (Yield) $0.00 (1.6%)
Volume 32,435
Average Daily Volume 28,401
Current FY EPS $8.23





Bayer AG (ADR) (BAYRY) Description

The Company offers products, including ethical pharmaceuticals and other health care products, agricultural products and polymers. Website:

News & Commentary

9 Executives Whose Ugly Comments and Actions We Can't (And Shouldn't) Forget

No, any PR isn't good PR -- especially when you're a corporate figurehead veering into racist, homophobic, or misogynistic territory.

Bargain Stocks In Europe’s Strongest Economy

What You Need to Know About Seattle Genetics' Biggest Growth Driver

Seattle Genetics (SGEN) successful Hodgkin's lymphoma drug Adcetris has an opportunity for significant growth if ongoing trials succeed.

Regeneron Pharmaceuticals' Q4 Profit Surges 51% on Strong Eylea Sales

Impressive Eylea sales growth within and outside the U.S., as well as increased collaborative revenue, pushes Regeneron's profit up 51%.

Here's Why Big Pharma is Rooting for Portola

Pfizer (PFE), Bristol-Myers (BMY), Johnson & Johnson (JNJ) and Bayer (BAYRY) stand to make big money if Portola's anti-coagulant antidote succeeds.

Sales of Pfizer Inc. and Bristol-Myers Squibb Co.'s Eliquis Thicken

Pfizer (PFE) and Bristol's (BMY) blood thinning drug Eliquis may be gaining ground on Johnson & Johnson (JNJ) and Boehringer.

Acetaminophen: 4 Things to Know About This Common Over-the-Counter Drug

The FDA recently issued a warning regarding liver damage caused by acetaminophen. Here are four things consumers and investors need to know about the drug, and how it could affect companies like Johnson & Johnson, Novartis, GlaxoSmithKline, and Zogenix.

FDA Okays First Two-Drug Treatment For Melanoma

GlaxoSmithKline receives FDA approval on a novel treatment combination for late-stage melanoma.

3 Reasons Regeneron Can Keep Rising in 2014

Regeneron has had a great run over the past 12 months. Will these 3 bullish indicators -- which also affect Bayer, Novartis, Roche, and Sanofi -- catapult the stock to new heights in 2014?

Bayer's Challenge in 2014? For Xofigo to Win Share From Johnson & Johnson's Zytiga

The market for prostate cancer treatment is $12 billion and growing, but it's getting crowded. That makes this year important as Bayer's Xofigo faces off against Johnson's Zytiga and Medivation's Xtandit.

See More BAYRY News...

BAYRY's Top Competitors

BAYRY $133.52 (-0.29%)
Current stock: BAYRY
JNJ $102.02 (-0.09%)
Current stock: JNJ
NVS $88.49 (0.82%)
Current stock: NVS
RHHBY $36.84 (0.19%)
Current stock: RHHBY